The Consequences of Saying No to a Hostile Takeover Bid
A report on hostile takeovers in the last five years suggests that shareholders should take a close look at which option creates most value, Steven Davidoff Solomon writes in the Deal Professor column.
View ArticleJudge Declines to Block Ackman From Voting in Board Fight at Allergan
William A. Ackman's hedge fund could vote its stake in Allergan in support of ousting directors at a meeting scheduled for Dec. 18, bolstering his effort to force the company into a sale.
View ArticleIn War Over Botox Maker Allergan, Technicalities Can Be Tricky
If you look at the fine print, a judge’s ruling this week may open up a new line of attack against the hedge fund manager William Ackman, Peter Henning and Steven Davidoff Solomon write.
View ArticleZoetis, an Animal Health Company, Says Ackman Has Taken a Stake
The activist investor William A. Ackman has acquired an 8.5 percent economic interest in the former animal health arm of Pfizer.
View ArticleAllergan Nears a Deal With Actavis to Block a Takeover by Valeant
At $62.5 billion, a deal between the drug makers Actavis and Allergan would be one of the biggest mergers of the year.
View ArticleZoetis to Buy Abbott’s Animal Health Assets
The animal health care company Zoetis, which has attracted the interest of the deal maker William A. Ackman, has made a deal of its own.
View ArticleAllergan Escapes Valeant’s Pursuit, Agreeing to Be Bought by Actavis
The $66 billion acquisition by Actavis would be the largest deal this year and would thwart the takeover effort of Valeant and William A. Ackman.
View ArticleNo Allergan Deal, but a $2.6 Billion Profit for Ackman
William Ackman appears to have been thwarted in his effort to partner with Valeant Pharmaceuticals on a takeover of Allergan, but losing may still feel like winning.
View ArticleOne Day, Two Deals and a Changed Calculus of Deal-Making
As the Allergan and Baker Hughes deals show, companies are struggling to justify a case against activist investors and hostile bidders, Steven Davidoff Solomon writes in the Deal Professor column.
View ArticleAckman Has Luck of a Loser, to the Tune of $2.2 Billion
William A. Ackman and Valeant Pharmaceuticals lost their hostile battle to buy Allergan and still came away with a total of $2.6 billion.
View ArticleMega-Mergers Popular Again on Wall Street
A pair of deals announced on Monday, worth $100 billion, brought the year’s total for American companies to $1.5 trillion, the highest since 2000.
View ArticleS.E.C. Seeks to Dismiss Insider Trading Lawsuit Involving Herbalife Shares
The Securities and Exchange Commission said it would not be able to proceed with the lawsuit because the two main witnesses it intended to call to testify are in Poland and had no plans to return to...
View ArticleAnti-Takeover Measures Often Hurt Investors
Defensive tactics can serve legitimate business interests, but many invite criticism that companies are eager to avoid, Reynolds Holding writes in Reuters Breakingviews.
View ArticleZoetis Adds Ackman Deputy to Its Board, Avoiding a Fight
The appointment of William F. Doyle, a top lieutenant at William Ackman’s hedge fund, comes after Pershing said it would hold talks with the veterinary medicine maker.
View ArticleEx-Federal Prosecutor in New York Joins Ackman’s Hedge Fund
The move reflects a growing trend of seasoned prosecutors’ bypassing the traditional career path of a job at a big law firm.
View Article
